The annual call for new topics is open.
To propose a new health condition that is not already considered by the UK NSC, please follow this link.
The deadline for submissions is midnight on Wednesday 6th December. More info
 
Current UK NSC recommendations > Blood group & RhD status and red cell alloantibodies

The UK NSC recommendation on Blood group & RhD status and red cell alloantibodies screening in pregnancy (currently under review)

 

This recommendation is currently being reviewed as part of the UK NSC's regular review cycle of all policies.

The review process began in Apr 2012 and is estimated to be completed by Mar 2014.

Recommendation Systematic population screening programme not recommended, clinical practice guidelines covered by NICE
 
Key downloads
 

Testing should be offered for blood group and RhD status and screening should be offered for atypical red cell alloantibodies.

 

Find general information about population health screening.

More about Blood group & RhD status and red cell alloantibodies

Identifying blood group, rhesus D status and red cell antibodies in pregnant women is important to prevent haemolytic disease of the newborn and to identify possible transfusion problems. Haemolytic disease of the newborn, or rhesus disease, happens when antibodies in a mother's blood attack her baby's blood cells. It may cause jaundice, severe anaemia, heart failure and death.

» Read more about rhesus disease on NHS Choices

Stakeholders

Faculty of Public Health
NHS Blood & Transplant
Royal College of General Practitioners
Royal College of Midwives
Royal College of Obstetricians and Gynaecologists
Royal College of Physicians
Royal College of Physicians and Surgeons of Glasgow
Royal College of Physicians of Edinburgh

The stakeholder groups will be involved when the recommendation is next reviewed. If you think your organisation should be added, please contact us. More information for stakeholders can be found in appendix C of the UK NSC evidence review process.

More options

Go to top